Related Experiment Video
Updated: Jul 18, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Recent progress in target therapy in colorectal cancer
Lara Maria Pasetto1, Alberto Bortolami, Cristina Falci
1Istituto Oncologico Veneto, Medical Oncology, 35128 Padova. laramary@libero.it
Anticancer Research
|November 11, 2006
Summary
Monoclonal antibodies like cetuximab and bevacizumab offer improved survival for colorectal cancer patients. These targeted therapies show superior efficacy compared to traditional chemotherapy, with ongoing research into optimal combinations.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Monoclonal antibodies represent a novel therapeutic class targeting specific cancer cell receptors.
- These antibodies can deliver payloads such as toxins or radioactive isotopes directly to tumor cells.
- Cetuximab and bevacizumab have emerged as significant agents in colorectal cancer management.
Purpose of the Study:
- To review the clinical applications, mechanisms of action, and safety profiles of monoclonal antibodies in colorectal cancer.
- To discuss the efficacy of cetuximab and bevacizumab in various treatment settings for colorectal carcinoma.
- To highlight the potential of these targeted agents in combination therapies.
Main Methods:
- Review of recent clinical studies and data on monoclonal antibody therapies.
- Analysis of mechanisms of action, including direct cellular effects and targeted delivery.
- Evaluation of safety profiles and clinical outcomes in patients with colorectal cancer.
Main Results:
- Cetuximab plus irinotecan is approved for second-line therapy in irinotecan-resistant colorectal cancer.
- Bevacizumab plus 5FU/LV demonstrated improved response and survival in first-line metastatic colorectal cancer.
- Combinations with oxaliplatin have shown promising results, doubling therapeutic outcomes.
Conclusions:
- Monoclonal antibodies provide superior therapeutic efficacy over traditional chemotherapy, evidenced by survival benefits in advanced or recurrent cancers.
- The precise mechanisms are still under investigation, but specific inhibition of tumor progression and metastasis genes is evident.
- Further research is required to identify optimal patient groups and drug combinations for enhanced therapeutic strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...